论文部分内容阅读
为了探讨促肝细胞生长素（PHGF）对人肝纤维化的影响．我们采用放射免疫法对21例用PHGF治疗及15例不用PHGF治疗的肝炎后肝硬化患者治疗前、后血清人Ⅲ型前胶原（hpcⅢ）、透明质酸（HA）水平进行检测．结果表明，治疗前、后hpcⅢ分别为328．0±167．0μg／L和236．7±92．5μg／L·HA分别为1455．2±722．8ng／ml和1142．8±556．0ng／ml，均明显降低（P＜0．05）。初步证明PHGF具有抗人肝纤维化作用。
To investigate the effect of hepatocyte growth-promoting factor (PHGF) on human liver fibrosis. We used radioimmunoassay to detect serum hpcⅢ and hyaluronic acid (HA) levels in 21 PHH-treated and 15 PHH-untreated patients with cirrhosis before and after treatment. The results showed that hpcⅢ before treatment and after treatment were 328.0 ± 167.0μg / L and 236.7 ± 92.5μg / L · HA respectively, which were 1455.2 ± 722.8ng / ml and 1142.8 ± 556.0ng / Ml, were significantly lower (P <0.05). Preliminary evidence that PHGF has anti-human liver fibrosis.